ALPS Medical Breakthroughs ETF
SBIO
26 hedge funds and large institutions have $16.6M invested in ALPS Medical Breakthroughs ETF in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 5 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
5.28% less ownership
Funds ownership: 19.84% → 14.55% (-5.3%)
7% less funds holding
Funds holding: 28 → 26 (-2)
21% less capital invested
Capital invested by funds: $20.9M → $16.6M (-$4.32M)
32% less call options, than puts
Call options by funds: $379K | Put options by funds: $554K
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.03M |
| 2 |
VF
Virtu Financial
New York
|
+$641K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$589K |
| 4 |
NAM
NTV Asset Management
Charleston,
West Virginia
|
+$392K |
| 5 |
MCM
Murphy Capital Management
Bedminster,
New Jersey
|
+$198K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$2.29M |
| 2 |
Credit Agricole
Montrouge Cedex,
France
|
-$1.9M |
| 3 |
LPL Financial
San Diego,
California
|
-$1.41M |
| 4 |
Goldman Sachs
New York
|
-$1.29M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$934K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Goldman Sachs
New York
| – | -$1.29M | -50,036 | Closed |
|
|
27
Credit Agricole
Montrouge Cedex,
France
| – | -$1.9M | -43,453 | Closed |
|
|
28
Citadel Advisors
Miami,
Florida
| – | -$934K | -36,239 | Closed |
|
29
Jane Street
New York
| – | -$615K | -23,855 | Closed |
|
30
Commonwealth Equity Services
Waltham,
Massachusetts
| – | -$235K | -9,132 | Closed |
|
|
CG
31
Cutler Group
San Francisco,
California
| – | +$78 | +3 | New |
|
SBIO Hedge Fund Activity: Q2 2017 in Review
26 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in ALPS Medical Breakthroughs ETF (SBIO) for Q2 2017, worth a combined $16.6M — down 21% from $20.9M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of SBIO and 3 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 8 added.
The largest buyer was UBS Group, adding an estimated $1.03M. The largest seller was Raymond James & Associates, cutting an estimated $2.29M.
- 26 institutional investors held ALPS Medical Breakthroughs ETF (SBIO) as of Q2 2017, down from 28 in Q1 2017.
- Funds reported $16.6M of ALPS Medical Breakthroughs ETF stock for Q2 2017, down 21% quarter-over-quarter.
- 3 funds opened new ALPS Medical Breakthroughs ETF positions in Q2 2017 and 5 closed out, a net change of -2 holders.
- The largest ALPS Medical Breakthroughs ETF buyer in Q2 2017 was UBS Group, an estimated $1.03M added.
- The largest ALPS Medical Breakthroughs ETF seller in Q2 2017 was Raymond James & Associates, an estimated $2.29M sold.
Based on aggregated 13F filings for Q2 2017.